Becton, Dickinson and Company (BDX)

Over the past six months, Becton, Dickinson & Co. (BDX) shares have experienced a decline. As of June 20, 2025, the share price was $168.42, representing a decline of 28.61% from June 24, 2024, when it was $235.91. The stock has dropped 3.5% over the past six months and 4.7% over the past 52 weeks, underperforming the Health Care Select Sector SPDR Fund (XLV) during the same periods. BDX has been trading below its 200-day and 50-day moving averages since early February 2025, indicating a recent bearish trend. Despite strong Q1 fiscal 2025 earnings reported on February 5, 2025, the stock fell 7.3% due to investor concerns over macroeconomic headwinds and foreign currency impacts. More recently, on May 1, 2025, BDX posted quarterly earnings of $3.35 per share, beating estimates, but revenue of $5.272 billion missed estimates. Analyst ratings have shown some downgrades.

BD's worldwide sales are generally not seasonal, but certain medical devices in the BD Medical segment and respiratory and flu diagnostic products in the BD Life Sciences segment do experience seasonality due to their relation to seasonal diseases like influenza. Demand for COVID-19 testing kits impacted revenue, with strong demand in 2021 followed by weakening demand as the pandemic eased. The company's inventory levels can also decrease in the first quarter due to the seasonal nature of some business aspects.

Becton, Dickinson and Company (BDX) is a leading global medical technology company that develops, manufactures, and sells a wide array of medical supplies, devices, laboratory equipment, and diagnostic products. The company operates within the Health Technology sector, specifically in the Medical Specialties or Medical Instruments & Supplies industry. BD's offerings cater to a diverse clientele, including healthcare institutions, life science researchers, clinical laboratories, industry professionals, the pharmaceutical sector, and the general public. BD operates through three main business segments: BD Medical, BD Life Sciences, and BD Interventional.

Becton, Dickinson & Co. has a robust global presence, with operations and sales extending worldwide. The company markets its products in various regions, including Europe, Japan, Asia Pacific, Canada, Latin America, the Middle East, and Africa. International revenue accounts for approximately 43% to 44% of the company's total business. BD maintains manufacturing facilities in multiple countries, such as Brazil, China, France, Germany, Hungary, India, Ireland, Japan, Korea, Mexico, Pakistan, Singapore, Spain, Sweden, the United Kingdom, and the US. The company's headquarters are located in Franklin Lakes, New Jersey, USA.

Becton, Dickinson & Co. has a long-standing reputation for innovation and quality in medical technology. The company is recognized as a comprehensive provider of medical technologies, supported by diverse product offerings and a significant international footprint. Factors such as pricing, quality, service, brand reputation, distribution capabilities, and promotional strategies influence its market share. BD invests in research, quality management, innovation, and productivity improvements to maintain its competitive edge. There haven't been widely reported major negative events significantly impacting BDX's brand reputation in the past year. The company continues to focus on advancing healthcare through innovative medical devices and solutions.

Becton, Dickinson & Co. has a diverse ownership base, primarily dominated by large financial institutions. Approximately 55.49% to 78.48% of the company's stock is owned by institutional investors, while individual retail investors hold around 21.39% to 22.99%. Insiders own under 1% of the company's shares. Major institutional owners and shareholders include Vanguard Group Inc., BlackRock, Inc., State Street Corp., T. Rowe Price Investment Management, Inc., Massachusetts Financial Services Co /ma/, Morgan Stanley, Geode Capital Management, LLC, and First Eagle Investment Management, LLC.